Timber Pharmaceuticals: Funding Only Into Q3 2021, But Some Hidden Value Remains

Timber Pharmaceuticals: Funding Only Into Q3 2021, But Some Hidden Value Remains

• Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on acquiring and developing therapeutics for orphan dermatologic diseases.
• Timber Pharmaceuticals is not in a great financial position with cash only at $10.3M (FYE 2020) on top of an escalating cash burn highlighting funding barely into Q3 2021.
• Timber Pharmaceuticals' pipeline consists of four mid-clinical-stage therapeutic programs (2 with ODD designation) and one pre-clinical also with ODD designation covering dermatological diseases with topical treatments.
• Timber Pharmaceuticals' critical next catalyst is TMB-001 and TMB-002's Phase 2b data readouts expected within the next 12 months which will likely be positive but have the potential for de-listing scenario downside.
• In summary, the author projects Timber Pharmaceuticals as a "hold" until Phase 2b results are posted in 1H 2022.

For further details see:

Timber Pharmaceuticals: Funding Only Into Q3 2021, But Some Hidden Value RemainsNews Provided by SeekingAlpha via QuoteMedia